Wall Street Zen Upgrades Avanos Medical (NYSE:AVNS) to Buy

Avanos Medical (NYSE:AVNS) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Other equities research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Avanos Medical Price Performance

AVNS stock opened at $13.51 on Friday. The stock has a market cap of $628.28 million, a PE ratio of -8.55 and a beta of 1.07. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $15.68. The company has a 50-day moving average price of $13.82 and a 200 day moving average price of $12.37. The company has a current ratio of 2.15, a quick ratio of 1.26 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.70 million. During the same period in the prior year, the company posted $0.43 EPS. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities research analysts anticipate that Avanos Medical will post 1.32 earnings per share for the current year.

Institutional Trading of Avanos Medical

Several institutional investors and hedge funds have recently modified their holdings of AVNS. Corient Private Wealth LLC purchased a new stake in shares of Avanos Medical in the fourth quarter valued at approximately $234,000. Alpine Global Management LLC bought a new position in Avanos Medical in the fourth quarter worth approximately $177,000. Vident Advisory LLC purchased a new position in Avanos Medical during the 4th quarter worth $585,000. State of Tennessee Department of Treasury increased its holdings in Avanos Medical by 50.0% during the 4th quarter. State of Tennessee Department of Treasury now owns 41,405 shares of the company’s stock worth $465,000 after purchasing an additional 13,799 shares during the period. Finally, EP Wealth Advisors LLC bought a new stake in Avanos Medical during the 4th quarter valued at $201,000. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.